Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 9:9:861076.
doi: 10.3389/fmed.2022.861076. eCollection 2022.

Road Toward a New Model of Care for Idiopathic Pulmonary Fibrosis in the Lazio Region

Rossella Di Bidino  1 , Paola Rogliani  2 , Alfredo Sebastiani  3 , Alberto Ricci  4 , Francesco Varone  5 , Giacomo Sgalla  5 , Bruno Iovene  5 , Teresa Bruni  5 , Maria Chiara Flore  5 , Michela D'Ascanio  4 , Francesco Cavalli  2 , Daniela Savi  6 , Loreta Di Michele  3 , Americo Cicchetti  1 , Luca Richeldi  5
Affiliations

Road Toward a New Model of Care for Idiopathic Pulmonary Fibrosis in the Lazio Region

Rossella Di Bidino et al. Front Med (Lausanne). .

Abstract

A timely, confirmed diagnosis of Idiopathic Pulmonary Fibrosis (IPF) has a significant impact on the evolution of the disease. The current model of care in the Lazio region (in Italy) was assessed on the basis of real-world data provided by the four reference centers responsible for diagnosing and treating IPF. The 5-year, population-based, retrospective longitudinal study provided the data that is at the basis of the current proposal for a new clinical and therapeutic pathway (DTCP) and has been shared with regional decision makers. A DTCP must be defined and based on four pillars: GPs, pulmonologists, IPF centers, and telemedicine. Each must play a role within a sort of hub-and-spoke model. IPF centers remain the hubs, while spokes are identified in trained GPs and pulmonologists.

Keywords: care pathway analysis; idiopathic pulmonary fibrosis; organizational analyses; real-world data analysis; therapeutic pathways.

PubMed Disclaimer

Conflict of interest statement

All authors has received a research grants from ALTEMS to participate to the study. For other studies, LR has received consulting fees from Boehringer Ingelheim, Roche, FibroGen, Celgene, RespiVant, Nitto, Bristol Myers Squibb, Pliant Therapeutics, Veracyte, CSL Behring, Novartis, and speaker honorarium from Boehringer Ingelheim, Roche, Zambon, CSL Behring and participated in Data Safety Monitoring Board or Advisory Boards for Boehringer Ingelheim, Roche, FibroGen, Veracyte. Departement of Experimental Medicine - Respiratory Medicine (Università di Roma “Tor Vergata”) was funded by Almirall, Boehringer Ingelheim, Chiesi Farmaceutici, Novartis, and Zambon. PR participated as a lecturer in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis and as an advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis. AS has received consulting fee from Boehringer Ingelheim, Roche and participated in Data Safety Monitoring Board or Advisory Boards for Roche. Then received support for attending meetings and/or travel from Roche. FV has received a speaker honorarium from from Boehringer Ingelheim, Roche. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Patients with confirmed diagnosis of IPF in the Lazio region from 2014 to 2018. Absolute numbers and incidence rates per 100,000 people (>45 years of age).
Figure 2
Figure 2
Pillars of a new model of care for IPF in the Lazio region.
See this image and copyright information in PMC

References

    1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. . An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. (2018) 198:e44–68. 10.1164/rccm.201807-1255ST - DOI - PubMed
    1. Aiello M, Bertorelli G, Bocchino M, Chetta A, Fiore-Donati A, Fois A, et al. . The earlier, the better: impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. (2017) 44:7–15. 10.1016/j.pupt.2017.02.005 - DOI - PubMed
    1. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. . INPULSIS trial investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. (2014) 370:2071–82. 10.1056/NEJMoa1402584 - DOI - PubMed
    1. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. . Pirfenidone in patients with idiopathic 261 pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. (2011) 377:1760–9. 10.1016/S0140-6736(11)60405-4 - DOI - PubMed
    1. Italian Drug Agency . Regime Di Rimborsabilita' E Prezzo Di Vendita A Seguito Di Nuove Indicazioni Terapeutiche Del Medicinale Per Uso Umano ≪Ofev≫. (2016). Available online at: https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto... (accessed May 16, 2022).

LinkOut - more resources